PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 1822447
PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 1822447
Personalized Medicine in Neurology Market Forecasts to 2032 - Global Analysis By Therapy Type (Pharmacogenomics, Digital Therapeutics, Biomarker-Based Diagnostics and Targeted Therapeutics), Technology, Application, End User and By Geography
According to Stratistics MRC, the Global Personalized Medicine in Neurology Market is accounted for $576.8 billion in 2025 and is expected to reach $1,021.1 billion by 2032 growing at a CAGR of 8.5% during the forecast period. Personalized medicine in neurology is a patient-centered approach that tailor's diagnosis, treatment, and prevention strategies to an individual's unique genetic, biomarker, environmental, and lifestyle profile. It moves beyond the "one-size-fits-all" model by integrating advanced technologies like genomics, neuroimaging, and data analytics to understand disease mechanisms at a personal level. This approach enhances precision in managing neurological disorders such as epilepsy, Alzheimer's disease, and multiple sclerosis, improving outcomes and minimizing side effects. Personalized neurology also fosters early detection and targeted therapies, empowering clinicians to deliver care that is more effective, predictive, and responsive to each patient's distinct neurological makeup.
Market Dynamics:
Driver:
Rising Prevalence of Neurological Disorders
The rising prevalence of neurological disorders is accelerating advancements in personalized medicine, transforming neurology into a more precise and patient-centric field. With increased demand, researchers are harnessing genetic, biomarker, and lifestyle data to tailor treatments for conditions like Alzheimer's and Parkinson's. This shift fosters innovation in diagnostics and therapeutics, empowering clinicians to deliver more effective, individualized care-ultimately improving outcomes and quality of life for millions affected by neurological diseases.
Restraint:
High Cost of Personalized Treatments
The high cost of personalized treatments in neurology significantly hinders accessibility and equity in care. Many patients, especially in low-resource settings, cannot afford advanced genomic testing or tailored therapies, leading to disparities in treatment outcomes. This financial barrier slows widespread adoption, limits clinical trials, and discourages investment in scalable solutions. Ultimately, it undermines the promise of personalized medicine to deliver precise, effective neurological care for all individuals.
Opportunity:
Advancements in Genomics and Molecular Diagnostics
Advancements in genomics and molecular diagnostics have revolutionized personalized medicine in neurology by enabling precise identification of genetic mutations and biomarkers. These innovations allow tailored treatments for conditions like epilepsy, Alzheimer's, and Parkinson's, improving efficacy and reducing side effects. Early diagnosis and risk prediction empower proactive care, while gene-targeted therapies offer hope for previously untreatable disorders. Together, they drive a transformative shift toward individualized, data-driven neurological healthcare.
Threat:
Complex Regulatory Landscape
The complex regulatory landscape significantly hampers the advancement of personalized medicine in neurology. Stringent approval processes, fragmented global standards, and slow adaptation to emerging technologies delay innovation and patient access. Regulatory ambiguity around genetic data and biomarkers further complicates clinical integration. These barriers discourage investment, stifle collaboration, and limit tailored treatment options, ultimately impeding progress in delivering precise, effective neurological care to patients who need it most.
Covid-19 Impact
The Covid-19 pandemic accelerated the adoption of personalized medicine in neurology by highlighting the need for precision care and remote diagnostics. It spurred innovation in telemedicine, digital health platforms, and genomic research, enabling tailored neurological treatments despite healthcare disruptions. However, resource diversion and delayed clinical trials temporarily hindered progress. Overall, the crisis underscored the value of individualized approaches in managing neurological conditions, fostering resilience and adaptability in care delivery.
The alzheimer's disease segment is expected to be the largest during the forecast period
The alzheimer's disease segment is expected to account for the largest market share during the forecast period, due to urgent need for more effective, individualized treatments. Personalized medicine enables early detection and tailored therapeutic strategies using genomics and biomarkers, which are especially critical in managing Alzheimer's progression. With increasing research investments and technological advancements, this segment benefits from precision diagnostics and targeted interventions, significantly improving patient outcomes and reducing the burden on caregivers and healthcare systems.
The microarray segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the microarray segment is predicted to witness the highest growth rate, due to its ability to analyze thousands of genetic markers simultaneously. This technology plays a pivotal role in identifying disease-specific biomarkers and tailoring treatments to individual neurological profiles. Its growing adoption in clinical settings for early diagnosis and personalized therapy selection enhances its market potential. As demand for precision medicine rises, microarrays offer scalable, cost-effective solutions that support the expansion of personalized neurology applications.
Region with largest share:
During the forecast period, the Asia Pacific region is expected to hold the largest market share due to its vast patient population, increasing healthcare investments, and growing awareness of neurological disorders. Countries like China, India, and Japan are rapidly adopting advanced diagnostic technologies and personalized treatment approaches. Government initiatives promoting genomics research and healthcare digitization further fuel market growth. The region's expanding medical infrastructure and rising demand for tailored therapies make it a key driver in the global neurology personalization landscape.
Region with highest CAGR:
Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, owing to robust research infrastructure, high healthcare spending, and early adoption of innovative technologies. The region benefits from strong collaborations between academic institutions, biotech firms, and healthcare providers, accelerating the development of genomic and molecular diagnostic tools. Favorable regulatory frameworks and increasing prevalence of neurological disorders like Alzheimer's and multiple sclerosis further boost demand for personalized treatments, positioning North America as a growth leader.
Key players in the market
Some of the key players profiled in the Personalized Medicine in Neurology Market include Roche Holding AG, Thermo Fisher Scientific Inc., Novartis AG, Becton, Dickinson and Company (BD), Biogen Inc., Merck & Co., Inc., Johnson & Johnson, Siemens Healthineers, Pfizer Inc., Abbott Laboratories, GlaxoSmithKline plc (GSK), Eli Lilly and Company, Amgen Inc., Illumina, Inc., Neurocrine Biosciences, Inc., QIAGEN N.V., PerkinElmer, Inc. and Agilent Technologies, Inc.
Key Developments:
In August 2025, Novartis has entered a collaboration with BioArctic to harness their BrainTransporter platform, aiming to develop novel neurological therapeutics. BioArctic will combine its BrainTransporter technology with a Novartis proprietary antibody to generate drug candidates.
In July 2025, Novartis has entered a collaboration with BioArctic to harness their BrainTransporter platform, aiming to develop novel neurological therapeutics. BioArctic will combine its BrainTransporter technology with a Novartis proprietary antibody to generate drug candidates.
Therapy Types Covered:
- Pharmacogenomics
- Digital Therapeutics
- Biomarker-Based Diagnostics
- Targeted Therapeutics
Technologies Covered:
- Next-Generation Sequencing (NGS)
- CRISPR-based Diagnostics
- Polymerase Chain Reaction (PCR)
- Microarray
- Other Technologies
Applications Covered:
- Alzheimer's Disease
- Multiple Sclerosis
- Parkinson's Disease
- Epilepsy
- Stroke
- Other Neurological Disorders
End Users Covered:
- Hospitals & Clinics
- Research Institutes
- Diagnostic Laboratories
- Pharmaceutical & Biotechnology Companies
Regions Covered:
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- Italy
- France
- Spain
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia
- New Zealand
- South Korea
- Rest of Asia Pacific
- South America
- Argentina
- Brazil
- Chile
- Rest of South America
- Middle East & Africa
- Saudi Arabia
- UAE
- Qatar
- South Africa
- Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
- Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
- Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
- Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
2 Preface
- 2.1 Abstract
- 2.2 Stake Holders
- 2.3 Research Scope
- 2.4 Research Methodology
- 2.4.1 Data Mining
- 2.4.2 Data Analysis
- 2.4.3 Data Validation
- 2.4.4 Research Approach
- 2.5 Research Sources
- 2.5.1 Primary Research Sources
- 2.5.2 Secondary Research Sources
- 2.5.3 Assumptions
3 Market Trend Analysis
- 3.1 Introduction
- 3.2 Drivers
- 3.3 Restraints
- 3.4 Opportunities
- 3.5 Threats
- 3.6 Technology Analysis
- 3.7 Application Analysis
- 3.8 End User Analysis
- 3.9 Emerging Markets
- 3.10 Impact of Covid-19
4 Porters Five Force Analysis
- 4.1 Bargaining power of suppliers
- 4.2 Bargaining power of buyers
- 4.3 Threat of substitutes
- 4.4 Threat of new entrants
- 4.5 Competitive rivalry
5 Global Personalized Medicine in Neurology Market, By Therapy Type
- 5.1 Introduction
- 5.2 Pharmacogenomics
- 5.3 Digital Therapeutics
- 5.4 Biomarker-Based Diagnostics
- 5.5 Targeted Therapeutics
6 Global Personalized Medicine in Neurology Market, By Technology
- 6.1 Introduction
- 6.2 Next-Generation Sequencing (NGS)
- 6.3 CRISPR-based Diagnostics
- 6.4 Polymerase Chain Reaction (PCR)
- 6.5 Microarray
- 6.6 Other Technologies
7 Global Personalized Medicine in Neurology Market, By Application
- 7.1 Introduction
- 7.2 Alzheimer's Disease
- 7.3 Multiple Sclerosis
- 7.4 Parkinson's Disease
- 7.5 Epilepsy
- 7.6 Stroke
- 7.7 Other Neurological Disorders
8 Global Personalized Medicine in Neurology Market, By End User
- 8.1 Introduction
- 8.2 Hospitals & Clinics
- 8.3 Research Institutes
- 8.4 Diagnostic Laboratories
- 8.5 Pharmaceutical & Biotechnology Companies
9 Global Personalized Medicine in Neurology Market, By Geography
- 9.1 Introduction
- 9.2 North America
- 9.2.1 US
- 9.2.2 Canada
- 9.2.3 Mexico
- 9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 Italy
- 9.3.4 France
- 9.3.5 Spain
- 9.3.6 Rest of Europe
- 9.4 Asia Pacific
- 9.4.1 Japan
- 9.4.2 China
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 New Zealand
- 9.4.6 South Korea
- 9.4.7 Rest of Asia Pacific
- 9.5 South America
- 9.5.1 Argentina
- 9.5.2 Brazil
- 9.5.3 Chile
- 9.5.4 Rest of South America
- 9.6 Middle East & Africa
- 9.6.1 Saudi Arabia
- 9.6.2 UAE
- 9.6.3 Qatar
- 9.6.4 South Africa
- 9.6.5 Rest of Middle East & Africa
10 Key Developments
- 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
- 10.2 Acquisitions & Mergers
- 10.3 New Product Launch
- 10.4 Expansions
- 10.5 Other Key Strategies
11 Company Profiling
- 11.1 Roche Holding AG
- 11.2 Thermo Fisher Scientific Inc.
- 11.3 Novartis AG
- 11.4 Becton, Dickinson and Company (BD)
- 11.5 Biogen Inc.
- 11.6 Merck & Co., Inc.
- 11.7 Johnson & Johnson
- 11.8 Siemens Healthineers
- 11.9 Pfizer Inc.
- 11.10 Abbott Laboratories
- 11.11 GlaxoSmithKline plc (GSK)
- 11.12 Eli Lilly and Company
- 11.13 Amgen Inc.
- 11.14 Illumina, Inc.
- 11.15 Neurocrine Biosciences, Inc.
- 11.16 QIAGEN N.V.
- 11.17 PerkinElmer, Inc.
- 11.18 Agilent Technologies, Inc.
List of Tables
- Table 1 Global Personalized Medicine in Neurology Market Outlook, By Region (2024-2032) ($MN)
- Table 2 Global Personalized Medicine in Neurology Market Outlook, By Therapy Type (2024-2032) ($MN)
- Table 3 Global Personalized Medicine in Neurology Market Outlook, By Pharmacogenomics (2024-2032) ($MN)
- Table 4 Global Personalized Medicine in Neurology Market Outlook, By Digital Therapeutics (2024-2032) ($MN)
- Table 5 Global Personalized Medicine in Neurology Market Outlook, By Biomarker-Based Diagnostics (2024-2032) ($MN)
- Table 6 Global Personalized Medicine in Neurology Market Outlook, By Targeted Therapeutics (2024-2032) ($MN)
- Table 7 Global Personalized Medicine in Neurology Market Outlook, By Technology (2024-2032) ($MN)
- Table 8 Global Personalized Medicine in Neurology Market Outlook, By Next-Generation Sequencing (NGS) (2024-2032) ($MN)
- Table 9 Global Personalized Medicine in Neurology Market Outlook, By CRISPR-based Diagnostics (2024-2032) ($MN)
- Table 10 Global Personalized Medicine in Neurology Market Outlook, By Polymerase Chain Reaction (PCR) (2024-2032) ($MN)
- Table 11 Global Personalized Medicine in Neurology Market Outlook, By Microarray (2024-2032) ($MN)
- Table 12 Global Personalized Medicine in Neurology Market Outlook, By Other Technologies (2024-2032) ($MN)
- Table 13 Global Personalized Medicine in Neurology Market Outlook, By Application (2024-2032) ($MN)
- Table 14 Global Personalized Medicine in Neurology Market Outlook, By Alzheimer's Disease (2024-2032) ($MN)
- Table 15 Global Personalized Medicine in Neurology Market Outlook, By Multiple Sclerosis (2024-2032) ($MN)
- Table 16 Global Personalized Medicine in Neurology Market Outlook, By Parkinson's Disease (2024-2032) ($MN)
- Table 17 Global Personalized Medicine in Neurology Market Outlook, By Epilepsy (2024-2032) ($MN)
- Table 18 Global Personalized Medicine in Neurology Market Outlook, By Stroke (2024-2032) ($MN)
- Table 19 Global Personalized Medicine in Neurology Market Outlook, By Other Neurological Disorders (2024-2032) ($MN)
- Table 20 Global Personalized Medicine in Neurology Market Outlook, By End User (2024-2032) ($MN)
- Table 21 Global Personalized Medicine in Neurology Market Outlook, By Hospitals & Clinics (2024-2032) ($MN)
- Table 22 Global Personalized Medicine in Neurology Market Outlook, By Research Institutes (2024-2032) ($MN)
- Table 23 Global Personalized Medicine in Neurology Market Outlook, By Diagnostic Laboratories (2024-2032) ($MN)
- Table 24 Global Personalized Medicine in Neurology Market Outlook, By Pharmaceutical & Biotechnology Companies (2024-2032) ($MN)
- Table 25 North America Personalized Medicine in Neurology Market Outlook, By Country (2024-2032) ($MN)
- Table 26 North America Personalized Medicine in Neurology Market Outlook, By Therapy Type (2024-2032) ($MN)
- Table 27 North America Personalized Medicine in Neurology Market Outlook, By Pharmacogenomics (2024-2032) ($MN)
- Table 28 North America Personalized Medicine in Neurology Market Outlook, By Digital Therapeutics (2024-2032) ($MN)
- Table 29 North America Personalized Medicine in Neurology Market Outlook, By Biomarker-Based Diagnostics (2024-2032) ($MN)
- Table 30 North America Personalized Medicine in Neurology Market Outlook, By Targeted Therapeutics (2024-2032) ($MN)
- Table 31 North America Personalized Medicine in Neurology Market Outlook, By Technology (2024-2032) ($MN)
- Table 32 North America Personalized Medicine in Neurology Market Outlook, By Next-Generation Sequencing (NGS) (2024-2032) ($MN)
- Table 33 North America Personalized Medicine in Neurology Market Outlook, By CRISPR-based Diagnostics (2024-2032) ($MN)
- Table 34 North America Personalized Medicine in Neurology Market Outlook, By Polymerase Chain Reaction (PCR) (2024-2032) ($MN)
- Table 35 North America Personalized Medicine in Neurology Market Outlook, By Microarray (2024-2032) ($MN)
- Table 36 North America Personalized Medicine in Neurology Market Outlook, By Other Technologies (2024-2032) ($MN)
- Table 37 North America Personalized Medicine in Neurology Market Outlook, By Application (2024-2032) ($MN)
- Table 38 North America Personalized Medicine in Neurology Market Outlook, By Alzheimer's Disease (2024-2032) ($MN)
- Table 39 North America Personalized Medicine in Neurology Market Outlook, By Multiple Sclerosis (2024-2032) ($MN)
- Table 40 North America Personalized Medicine in Neurology Market Outlook, By Parkinson's Disease (2024-2032) ($MN)
- Table 41 North America Personalized Medicine in Neurology Market Outlook, By Epilepsy (2024-2032) ($MN)
- Table 42 North America Personalized Medicine in Neurology Market Outlook, By Stroke (2024-2032) ($MN)
- Table 43 North America Personalized Medicine in Neurology Market Outlook, By Other Neurological Disorders (2024-2032) ($MN)
- Table 44 North America Personalized Medicine in Neurology Market Outlook, By End User (2024-2032) ($MN)
- Table 45 North America Personalized Medicine in Neurology Market Outlook, By Hospitals & Clinics (2024-2032) ($MN)
- Table 46 North America Personalized Medicine in Neurology Market Outlook, By Research Institutes (2024-2032) ($MN)
- Table 47 North America Personalized Medicine in Neurology Market Outlook, By Diagnostic Laboratories (2024-2032) ($MN)
- Table 48 North America Personalized Medicine in Neurology Market Outlook, By Pharmaceutical & Biotechnology Companies (2024-2032) ($MN)
- Table 49 Europe Personalized Medicine in Neurology Market Outlook, By Country (2024-2032) ($MN)
- Table 50 Europe Personalized Medicine in Neurology Market Outlook, By Therapy Type (2024-2032) ($MN)
- Table 51 Europe Personalized Medicine in Neurology Market Outlook, By Pharmacogenomics (2024-2032) ($MN)
- Table 52 Europe Personalized Medicine in Neurology Market Outlook, By Digital Therapeutics (2024-2032) ($MN)
- Table 53 Europe Personalized Medicine in Neurology Market Outlook, By Biomarker-Based Diagnostics (2024-2032) ($MN)
- Table 54 Europe Personalized Medicine in Neurology Market Outlook, By Targeted Therapeutics (2024-2032) ($MN)
- Table 55 Europe Personalized Medicine in Neurology Market Outlook, By Technology (2024-2032) ($MN)
- Table 56 Europe Personalized Medicine in Neurology Market Outlook, By Next-Generation Sequencing (NGS) (2024-2032) ($MN)
- Table 57 Europe Personalized Medicine in Neurology Market Outlook, By CRISPR-based Diagnostics (2024-2032) ($MN)
- Table 58 Europe Personalized Medicine in Neurology Market Outlook, By Polymerase Chain Reaction (PCR) (2024-2032) ($MN)
- Table 59 Europe Personalized Medicine in Neurology Market Outlook, By Microarray (2024-2032) ($MN)
- Table 60 Europe Personalized Medicine in Neurology Market Outlook, By Other Technologies (2024-2032) ($MN)
- Table 61 Europe Personalized Medicine in Neurology Market Outlook, By Application (2024-2032) ($MN)
- Table 62 Europe Personalized Medicine in Neurology Market Outlook, By Alzheimer's Disease (2024-2032) ($MN)
- Table 63 Europe Personalized Medicine in Neurology Market Outlook, By Multiple Sclerosis (2024-2032) ($MN)
- Table 64 Europe Personalized Medicine in Neurology Market Outlook, By Parkinson's Disease (2024-2032) ($MN)
- Table 65 Europe Personalized Medicine in Neurology Market Outlook, By Epilepsy (2024-2032) ($MN)
- Table 66 Europe Personalized Medicine in Neurology Market Outlook, By Stroke (2024-2032) ($MN)
- Table 67 Europe Personalized Medicine in Neurology Market Outlook, By Other Neurological Disorders (2024-2032) ($MN)
- Table 68 Europe Personalized Medicine in Neurology Market Outlook, By End User (2024-2032) ($MN)
- Table 69 Europe Personalized Medicine in Neurology Market Outlook, By Hospitals & Clinics (2024-2032) ($MN)
- Table 70 Europe Personalized Medicine in Neurology Market Outlook, By Research Institutes (2024-2032) ($MN)
- Table 71 Europe Personalized Medicine in Neurology Market Outlook, By Diagnostic Laboratories (2024-2032) ($MN)
- Table 72 Europe Personalized Medicine in Neurology Market Outlook, By Pharmaceutical & Biotechnology Companies (2024-2032) ($MN)
- Table 73 Asia Pacific Personalized Medicine in Neurology Market Outlook, By Country (2024-2032) ($MN)
- Table 74 Asia Pacific Personalized Medicine in Neurology Market Outlook, By Therapy Type (2024-2032) ($MN)
- Table 75 Asia Pacific Personalized Medicine in Neurology Market Outlook, By Pharmacogenomics (2024-2032) ($MN)
- Table 76 Asia Pacific Personalized Medicine in Neurology Market Outlook, By Digital Therapeutics (2024-2032) ($MN)
- Table 77 Asia Pacific Personalized Medicine in Neurology Market Outlook, By Biomarker-Based Diagnostics (2024-2032) ($MN)
- Table 78 Asia Pacific Personalized Medicine in Neurology Market Outlook, By Targeted Therapeutics (2024-2032) ($MN)
- Table 79 Asia Pacific Personalized Medicine in Neurology Market Outlook, By Technology (2024-2032) ($MN)
- Table 80 Asia Pacific Personalized Medicine in Neurology Market Outlook, By Next-Generation Sequencing (NGS) (2024-2032) ($MN)
- Table 81 Asia Pacific Personalized Medicine in Neurology Market Outlook, By CRISPR-based Diagnostics (2024-2032) ($MN)
- Table 82 Asia Pacific Personalized Medicine in Neurology Market Outlook, By Polymerase Chain Reaction (PCR) (2024-2032) ($MN)
- Table 83 Asia Pacific Personalized Medicine in Neurology Market Outlook, By Microarray (2024-2032) ($MN)
- Table 84 Asia Pacific Personalized Medicine in Neurology Market Outlook, By Other Technologies (2024-2032) ($MN)
- Table 85 Asia Pacific Personalized Medicine in Neurology Market Outlook, By Application (2024-2032) ($MN)
- Table 86 Asia Pacific Personalized Medicine in Neurology Market Outlook, By Alzheimer's Disease (2024-2032) ($MN)
- Table 87 Asia Pacific Personalized Medicine in Neurology Market Outlook, By Multiple Sclerosis (2024-2032) ($MN)
- Table 88 Asia Pacific Personalized Medicine in Neurology Market Outlook, By Parkinson's Disease (2024-2032) ($MN)
- Table 89 Asia Pacific Personalized Medicine in Neurology Market Outlook, By Epilepsy (2024-2032) ($MN)
- Table 90 Asia Pacific Personalized Medicine in Neurology Market Outlook, By Stroke (2024-2032) ($MN)
- Table 91 Asia Pacific Personalized Medicine in Neurology Market Outlook, By Other Neurological Disorders (2024-2032) ($MN)
- Table 92 Asia Pacific Personalized Medicine in Neurology Market Outlook, By End User (2024-2032) ($MN)
- Table 93 Asia Pacific Personalized Medicine in Neurology Market Outlook, By Hospitals & Clinics (2024-2032) ($MN)
- Table 94 Asia Pacific Personalized Medicine in Neurology Market Outlook, By Research Institutes (2024-2032) ($MN)
- Table 95 Asia Pacific Personalized Medicine in Neurology Market Outlook, By Diagnostic Laboratories (2024-2032) ($MN)
- Table 96 Asia Pacific Personalized Medicine in Neurology Market Outlook, By Pharmaceutical & Biotechnology Companies (2024-2032) ($MN)
- Table 97 South America Personalized Medicine in Neurology Market Outlook, By Country (2024-2032) ($MN)
- Table 98 South America Personalized Medicine in Neurology Market Outlook, By Therapy Type (2024-2032) ($MN)
- Table 99 South America Personalized Medicine in Neurology Market Outlook, By Pharmacogenomics (2024-2032) ($MN)
- Table 100 South America Personalized Medicine in Neurology Market Outlook, By Digital Therapeutics (2024-2032) ($MN)
- Table 101 South America Personalized Medicine in Neurology Market Outlook, By Biomarker-Based Diagnostics (2024-2032) ($MN)
- Table 102 South America Personalized Medicine in Neurology Market Outlook, By Targeted Therapeutics (2024-2032) ($MN)
- Table 103 South America Personalized Medicine in Neurology Market Outlook, By Technology (2024-2032) ($MN)
- Table 104 South America Personalized Medicine in Neurology Market Outlook, By Next-Generation Sequencing (NGS) (2024-2032) ($MN)
- Table 105 South America Personalized Medicine in Neurology Market Outlook, By CRISPR-based Diagnostics (2024-2032) ($MN)
- Table 106 South America Personalized Medicine in Neurology Market Outlook, By Polymerase Chain Reaction (PCR) (2024-2032) ($MN)
- Table 107 South America Personalized Medicine in Neurology Market Outlook, By Microarray (2024-2032) ($MN)
- Table 108 South America Personalized Medicine in Neurology Market Outlook, By Other Technologies (2024-2032) ($MN)
- Table 109 South America Personalized Medicine in Neurology Market Outlook, By Application (2024-2032) ($MN)
- Table 110 South America Personalized Medicine in Neurology Market Outlook, By Alzheimer's Disease (2024-2032) ($MN)
- Table 111 South America Personalized Medicine in Neurology Market Outlook, By Multiple Sclerosis (2024-2032) ($MN)
- Table 112 South America Personalized Medicine in Neurology Market Outlook, By Parkinson's Disease (2024-2032) ($MN)
- Table 113 South America Personalized Medicine in Neurology Market Outlook, By Epilepsy (2024-2032) ($MN)
- Table 114 South America Personalized Medicine in Neurology Market Outlook, By Stroke (2024-2032) ($MN)
- Table 115 South America Personalized Medicine in Neurology Market Outlook, By Other Neurological Disorders (2024-2032) ($MN)
- Table 116 South America Personalized Medicine in Neurology Market Outlook, By End User (2024-2032) ($MN)
- Table 117 South America Personalized Medicine in Neurology Market Outlook, By Hospitals & Clinics (2024-2032) ($MN)
- Table 118 South America Personalized Medicine in Neurology Market Outlook, By Research Institutes (2024-2032) ($MN)
- Table 119 South America Personalized Medicine in Neurology Market Outlook, By Diagnostic Laboratories (2024-2032) ($MN)
- Table 120 South America Personalized Medicine in Neurology Market Outlook, By Pharmaceutical & Biotechnology Companies (2024-2032) ($MN)
- Table 121 Middle East & Africa Personalized Medicine in Neurology Market Outlook, By Country (2024-2032) ($MN)
- Table 122 Middle East & Africa Personalized Medicine in Neurology Market Outlook, By Therapy Type (2024-2032) ($MN)
- Table 123 Middle East & Africa Personalized Medicine in Neurology Market Outlook, By Pharmacogenomics (2024-2032) ($MN)
- Table 124 Middle East & Africa Personalized Medicine in Neurology Market Outlook, By Digital Therapeutics (2024-2032) ($MN)
- Table 125 Middle East & Africa Personalized Medicine in Neurology Market Outlook, By Biomarker-Based Diagnostics (2024-2032) ($MN)
- Table 126 Middle East & Africa Personalized Medicine in Neurology Market Outlook, By Targeted Therapeutics (2024-2032) ($MN)
- Table 127 Middle East & Africa Personalized Medicine in Neurology Market Outlook, By Technology (2024-2032) ($MN)
- Table 128 Middle East & Africa Personalized Medicine in Neurology Market Outlook, By Next-Generation Sequencing (NGS) (2024-2032) ($MN)
- Table 129 Middle East & Africa Personalized Medicine in Neurology Market Outlook, By CRISPR-based Diagnostics (2024-2032) ($MN)
- Table 130 Middle East & Africa Personalized Medicine in Neurology Market Outlook, By Polymerase Chain Reaction (PCR) (2024-2032) ($MN)
- Table 131 Middle East & Africa Personalized Medicine in Neurology Market Outlook, By Microarray (2024-2032) ($MN)
- Table 132 Middle East & Africa Personalized Medicine in Neurology Market Outlook, By Other Technologies (2024-2032) ($MN)
- Table 133 Middle East & Africa Personalized Medicine in Neurology Market Outlook, By Application (2024-2032) ($MN)
- Table 134 Middle East & Africa Personalized Medicine in Neurology Market Outlook, By Alzheimer's Disease (2024-2032) ($MN)
- Table 135 Middle East & Africa Personalized Medicine in Neurology Market Outlook, By Multiple Sclerosis (2024-2032) ($MN)
- Table 136 Middle East & Africa Personalized Medicine in Neurology Market Outlook, By Parkinson's Disease (2024-2032) ($MN)
- Table 137 Middle East & Africa Personalized Medicine in Neurology Market Outlook, By Epilepsy (2024-2032) ($MN)
- Table 138 Middle East & Africa Personalized Medicine in Neurology Market Outlook, By Stroke (2024-2032) ($MN)
- Table 139 Middle East & Africa Personalized Medicine in Neurology Market Outlook, By Other Neurological Disorders (2024-2032) ($MN)
- Table 140 Middle East & Africa Personalized Medicine in Neurology Market Outlook, By End User (2024-2032) ($MN)
- Table 141 Middle East & Africa Personalized Medicine in Neurology Market Outlook, By Hospitals & Clinics (2024-2032) ($MN)
- Table 142 Middle East & Africa Personalized Medicine in Neurology Market Outlook, By Research Institutes (2024-2032) ($MN)
- Table 143 Middle East & Africa Personalized Medicine in Neurology Market Outlook, By Diagnostic Laboratories (2024-2032) ($MN)
- Table 144 Middle East & Africa Personalized Medicine in Neurology Market Outlook, By Pharmaceutical & Biotechnology Companies (2024-2032) ($MN)
